Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance

NEW YORK — Tempus said on Wednesday that its cancer biomarker alliance with Bristol Myers Squibb has been expanded to include RNA-based targets.

According to Tempus, it has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new biomarkers related to undisclosed cancer subtypes. Under the expanded deal, Bristol Myers Squibb has licensed from Tempus terabytes of additional data cohorts across multiple tumor types, which will be analyzed with a focus on RNA expression targets.

Additional terms were not disclosed.

"Our work with Bristol Myers Squibb has made it possible to transform terabytes of data into clinically relevant insight by stratifying diseases into key molecular subtypes and uncovering potentially better ways to treat patients going forward," Tempus Chief Operating Officer Ryan Fukushima said in a statement.

In December, Chicago-based Tempus raised $200 million in a new Series G2 financing round and announced an oncology testing alliance with Bayer.